Poor treatment outcome and associated risk factors among patients with isoniazid mono-resistant tuberculosis: A systematic review and meta-analysis
PLOS ONE · 19.07.2023 · 18 (7) · e0286194
DOI: 10.1371/journal.pone.0286194 ↗Kurz gefasst
Metaanalyse in der Zeitschrift PLOS ONE, online erschienen am 19.07.2023. Verfasst von Ayinalem Alemu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Ethiopian Public Health Institute, Addis Ababa, Ethiopia. Hauptthemen laut MEDLINE: Isoniazid, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS.
Abstract (Originalsprache)
Background
To date, isoniazid mono-resistant tuberculosis (TB) is becoming an emerging global public health problem. It is associated with poor treatment outcome. Different studies have assessed the treatment outcome of isoniazid mono-resistant TB cases, however, the findings are inconsistent and there is limited global comprehensive report. Thus, this study aimed to assess the poor treatment outcome and its associated risk factors among patients with isoniazid mono-resistant TB.
Methods
Studies that reported the treatment outcomes and associated factors among isoniazid mono-resistant TB were searched from electronic databases and other sources. We used Joana Briggs Institute critical appraisal tool to assess the study’s quality. We assessed publication bias through visual inspection of the funnel plot and confirmed by Egger’s regression test. We used STATA version 17 for statistical analysis.
Results
Among 347 studies identified from the whole search, data were extracted from 25 studies reported from 47 countries. The pooled successful and poor treatment outcomes were 78% (95%CI; 74%-83%) and 22% (95%CI; 17%-26%), respectively. Specifically, complete, cure, treatment failure, mortality, loss to follow-up and relapse rates were 34%(95%CI; 17%-52%), 62% (95%CI; 50%-73%), 5% (95%CI; 3%-7%), 6% (95%CI; 4%-8%), 12% (95%CI; 8%-17%), and 1.7% (95%CI; 0.4%-3.1%), respectively. Higher prevalence of pooled poor treatment outcome was found in the South East Asian Region (estimate; 40%, 95%C; 34%-45%), and African Region (estimate; 33%, 95%CI; 24%-42%). Previous TB treatment (OR; 1.74, 95%CI; 1.15–2.33), having cancer (OR; 3.53, 95%CI; 1.43–5.62), and being initially smear positive (OR; 1.26, 95%CI; 1.08–1.43) were associated with poor treatment outcome. While those patients who took rifampicin in the continuation phase (OR; 0.22, 95%CI; 0.04–0.41), had extrapulmonary TB (OR; 0.70, 95%CI; 0.55–0.85), and took second-line injectable drugs (OR; 0.54, 95%CI; 0.33–0.75) had reduced risk of poor treatment outcome.
Conclusion
Isoniazid mono-resistant TB patients had high poor treatment outcome. Thus, determination of isoniazid resistance pattern for all bacteriologically confirmed TB cases is critical for successful treatment outcome. PROSPERO registration number: CRD42022372367
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
- Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.
- St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
- Addis Ababa Health Bureau, Addis Ababa, Ethiopia.
- USAID Eliminate TB Project, Management Sciences for Health, Addis Ababa, Ethiopia.
ORCID-Profile: Ayinalem Alemu, Getu Diriba
Förderung
- FIC NIH HHS
Zitieren
APA
Alemu, A., Bitew, Z. W., Diriba, G., Seid, G., Moga, S., Abdella, S., Gashu, E., Eshetu, K., Tollera, G., Dangisso, M. H., & Gumi, B. (2023). Poor treatment outcome and associated risk factors among patients with isoniazid mono-resistant tuberculosis: A systematic review and meta-analysis. PLOS ONE, 18(7), e0286194. https://doi.org/10.1371/journal.pone.0286194
Vancouver
Alemu A, Bitew ZW, Diriba G, Seid G, Moga S, Abdella S, et al. Poor treatment outcome and associated risk factors among patients with isoniazid mono-resistant tuberculosis: A systematic review and meta-analysis. PLOS ONE. 2023;18(7):e0286194. doi:10.1371/journal.pone.0286194
BibTeX
@article{Alemu2023,
author = {Alemu, Ayinalem and Bitew, Zebenay Workneh and Diriba, Getu and Seid, Getachew and Moga, Shewki and Abdella, Saro and Gashu, Emebet and Eshetu, Kirubel and Tollera, Getachew and Dangisso, Mesay Hailu and Gumi, Balako},
title = {Poor treatment outcome and associated risk factors among patients with isoniazid mono-resistant tuberculosis: A systematic review and meta-analysis},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {7},
pages = {e0286194},
doi = {10.1371/journal.pone.0286194}
}
EUVIMED